12:18 PM · 20 April 2022

Abbott Laboratories stock plunges in pre-market despite upbeat quarterly results

Abbott Laboratories (ABT.US) stock fell over 2.0% in pre-market despite the fact that medical devices and health care companies posted quarterly figures which topped market estimates. 

  • Company earned $1.73 on revenue of $11.9B boosted mainly by high demand for its COVID-19 test kits and other medical devices. Meanwhile analysts expected earnings of $1.47 on revenue of $11.04B.
  • Abbott expects a full-year 2022 diluted EPS on a GAAP basis around $3.35 and projected adjusted diluted EPS of at least $4.70 remains unchanged.
  • Guidance for the current fiscal year includes projected COVID-19 testing-related sales of approximately $4.5 billion, which Abbott expects to largely occur in the first half of the year and will update on a quarterly basis.

Abbott Laboratories (ABT.US) stock has been moving within an ascending channel since the end of February 2022. However price moved lower following the releases of quarterly figures and is currently approaching the lower limit of the formation. Should break lower occur, downward move may accelerate towards local support at $114.10. Source: xStation5

30 October 2026, 2:16 PM

US OPEN: Bloody end to the quarter. Intel loses nearly 1/3 of its value, and the crypto market shakes off a hack on the largest exchange.

30 October 2026, 11:08 AM

Market Wrap: Binance Hack Shakes Markets. European Equities Under Pressure

30 October 2026, 9:27 AM

Intel has come face to face with reality. A Turnaround is still a long way off.

29 October 2026, 10:25 PM

Amazon: Record-breaking operating margin outshined by capex growth

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits